Butanamide, 3-methyl-N-propyl

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Butanamide, 3-methyl-N-propyl
• 英文别名: 3-methyl-N-propylbutanamide
• 化学式: C₈H₁₇NO
• mdl: MFCD02860558
• 分子量: 143.23
• InChiKey: XBUJEXWMTCJERJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正己胺 、 异戊酸酐 、 正丙胺 生成 Butanamide, 3-methyl-N-propyl
  参考文献：
  名称：

  HIRAKI, YUJI;TAI, AKIRA, CHEM. LETT., 1982, N 3, 341-344

  摘要：

  DOI：

文献信息

• N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20180111905A1

  公开（公告）日：2018-04-26

  The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

  本发明涉及一种N2-(2-甲氧基苯基)嘧啶衍生物，其制备方法，以及包含其作为活性成分的用于预防或治疗癌症的药物组合物。本发明的N2-(2-甲氧基苯基)嘧啶衍生物，其光学异构体，或其药学上可接受的盐对抑制间变性淋巴瘤激酶（ALK）活性非常有效，从而可以提高对具有间变性淋巴瘤激酶（ALK）融合蛋白如EML4-ALK和NPM-ALK的癌细胞的治疗效果，因此可以有效地用作预防或治疗癌症的药物组合物。
• THAILANSTATIN ANALOGS
  申请人：pH Pharma Co., Ltd.

  公开号：US20190084996A1

  公开（公告）日：2019-03-21

  The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

  该发明提供了新型细胞毒化合物和包含这些细胞毒化合物和细胞结合剂的细胞毒结合物。更具体地，本发明涉及新型的thailanstatin A类似物，可用作抗体药物结合物中的细胞毒小分子毒素。本发明还涉及包括这些细胞毒化合物和ADCs的组合物，以及使用这些毒素和ADCs治疗包括癌症在内的病理状况的方法。
• NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF
  申请人：Yoo Jeong Soo

  公开号：US20120219495A1

  公开（公告）日：2012-08-30

  Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.

  提供的是一种新结构的交桥四氮杂大环化合物，可用作诊断成像的造影剂或放射性药物，以及一种制备该化合物的方法。所披露的四氮杂大环化合物能够在较低温度下形成稳定的金属配合物，并且与生物活性物质或化学活性物质相比，易于共轭。
• [EN] NEW AMIDE DERIVATIVES OF 2,2,3,3-TETRAMETHYLCYCLOPROPANE CARBOXYLIC ACID<br/>[FR] NOUVEAUX DERIVES D'AMIDE D'ACIDE CARBOXYLIQUE DE 2,2,3,3-TETRAMETHYLCYCLOPROPANE
  申请人：YISSUM RES DEV CO

  公开号：WO2004076432A1

  公开（公告）日：2004-09-10

  The invention relates to new 2,2,3,3-tetramethylcyclopropane carboxamide derivative compounds, pharmaceutical compositions thereof and uses thereof for treating psychotic disorders, neurodegenerative diseases, epilepsy and pain.

  这项发明涉及新的2,2,3,3-四甲基环丙烷羧酰胺衍生物化合物，其药物组成部分以及用于治疗精神病性障碍、神经退行性疾病、癫痫和疼痛的用途。
• [EN] AMIDE DERIVATIVES OF VALPROIC ACID AND USES THEREOF<br/>[FR] DÉRIVÉS AMIDE D'ACIDE VALPROÏQUE ET LEURS UTILISATIONS
  申请人：YISSUM RES DEV CO

  公开号：WO2011039746A1

  公开（公告）日：2011-04-07

  Amide derivatives of valproic acid are provided along their use in the treatment of epilepsy.

  戊二酸酰胺衍生物及其在癫痫治疗中的应用。